Ok you all seem like expectant fathers (and an occasional mother).
There is no real information. For me I bought the stock knowing the risks and rewards. Astera could be right, I am betting against it.
I am a long term shareholder who believes AOD has a good chance of being the top weight loss drug, with good weight loss, excellent tolerability (unlike most other types on the market or trying to make it), potential low dose seemingy very attractive for production. If at these levels the risk/reward is balanced, if it goes lower I will buy, if it goes higher before the announcment then I will hold.
The phase IIb trial is just that, a trial... nobody knows, except maybe the statistican at this stage. Can't wait to see what he/she reports.
Add to My Watchlist
What is My Watchlist?